Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States
Current Oncology · 2024
DOI: 10.3390/curroncol31090420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Helen H Moon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Southern California, Riverside, CA 92505, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck.
Abstract (Originalsprache)
For patients with locally advanced/metastatic urothelial carcinoma (la/mUC), first-line (1L) treatment with platinum-based chemotherapy (PBC) followed by avelumab 1L maintenance (1LM) is a recommended therapy per treatment guidelines in patients without disease progression. However, contemporary real-world (rw) data among patients receiving this treatment are necessary to understand clinical outcomes and optimal treatment sequencing. This retrospective cohort study analyzed rw treatment patterns and clinical outcomes, including overall survival (rwOS) and progression-free survival (rwPFS), in patients with la/mUC receiving avelumab 1LM. From the Flatiron Health database, 214 patients who received avelumab 1LM following 1L PBC were included. From the start of avelumab 1LM, median rwOS was 23.8 months (95% CI: 18.2—not estimable [NE]) and median rwPFS was 5.1 months (95% CI: 4.1–7.0). A total of 96 patients received second-line (2L) therapy, with 53 receiving enfortumab vedotin (EV). From the start of 2L EV, median rwOS was 11.2 months (95% CI: 6.8—NE) and median rwPFS was 4.9 months (95% CI: 3.9–8.8). Treatment patterns and clinical outcomes in this study align with guidelines and outcomes observed in the JAVELIN Bladder 100 and EV-301 clinical trials and other rw studies, supporting the use of 1L PBC followed by avelumab 1LM and 2L EV for eligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kaiser Permanente Southern California, Riverside, CA 92505, USA.
- Merck Healthcare KGaA, 64293 Darmstadt, Germany.
- EMD Serono, Inc., Rockland, MA 02370, USA.
- Genesis Research Group, Hoboken, NJ 07030, USA.
ORCID-Profile: Valerie Morris, Andrew Rava
Förderung
- Merck
Zitieren
APA
Moon, H. H., Kearney, M., Mahmoudpour, S. H., Ike, C., Morris, V., Rava, A., Kim, S., Sun, H., Boyd, M., & Gomez Rey, G. (2024). Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States. Current Oncology. https://doi.org/10.3390/curroncol31090420
Vancouver
Moon HH, Kearney M, Mahmoudpour SH, Ike C, Morris V, Rava A, et al. Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States. Current Oncology. 2024. doi:10.3390/curroncol31090420
BibTeX
@article{Moon2024,
author = {Moon, Helen H and Kearney, Mairead and Mahmoudpour, Seyed Hamidreza and Ike, Chiemeka and Morris, Valerie and Rava, Andrew and Kim, Sonia and Sun, Haiyan and Boyd, Marley and Gomez Rey, Gabriel},
title = {Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31090420}
}
EUVIMED